Table 2 The main characteristics of the included studies of SNPs in the promoter region of MIR17HG in cancers
Cancer patients | Controls | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allele | Genotype | Allele | Genotype | HWE of control (p-value) | |||||||||||
Polymorphisms | Authors (year) | Cancer types | Genotyping methods | A | a | AA | Aa | aa | A | a | AA | Aa | aa | ||
rs9588884 C> G | Jie et al. (2024)[41] | Endometrial Cancer | PCR-LDR | 502 | 294 | 149 | 204 | 45 | 481 | 359 | 133 | 215 | 72 | 0.347 | |
Wang et al. (2022)[42] | Breast Cancer | TaqMan assay | 469 | 361 | 130 | 209 | 76 | 458 | 382 | 122 | 214 | 84 | 0.574 | ||
Huang et al. (2019)[27] | CSCC | Taqman assay | 451 | 259 | 138 | 175 | 42 | 431 | 347 | 117 | 197 | 75 | 0.625 | ||
Sun et al. (2017)[26] | Colorectal Cancer | TaqMan assay | 1118 | 630 | 334 | 450 | 90 | 1280 | 984 | 350 | 580 | 202 | 0.152 | ||
rs982873 T> C | Jie et al. (2024)[41] | Endometrial Cancer | PCR-LDR | 490 | 306 | 140 | 210 | 48 | 456 | 384 | 119 | 218 | 83 | 0.348 | |
Wang et al. (2022)[42] | Breast Cancer | TaqMan assay | 482 | 348 | 135 | 212 | 68 | 474 | 366 | 126 | 222 | 72 | 0.125 | ||
Huang et al. (2019)[27] | CSCC | PCR-RFLP | 405 | 305 | 110 | 185 | 60 | 448 | 330 | 125 | 198 | 66 | 0.408 | ||
Sun et al. (2017)[26] | Colorectal Cancer | TaqMan assay | 1041 | 707 | 280 | 481 | 113 | 1242 | 1022 | 330 | 582 | 220 | 0.200 | ||
rs1813389 A> G | Wang et al. (2022)[42] | Breast Cancer | TaqMan assay | 483 | 347 | 138 | 207 | 70 | 466 | 374 | 128 | 210 | 82 | 0.804 | |
Huang et al. (2019)[27] | CSCC | PCR-RFLP | 419 | 291 | 125 | 169 | 61 | 476 | 302 | 145 | 186 | 58 | 0.896 | ||
Sun et al. (2017)[26] | Colorectal Cancer | TaqMan assay | 1052 | 696 | 295 | 462 | 117 | 1319 | 945 | 371 | 577 | 184 | 0.106 | ||